{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2017"],"data_sharing_plan":["IPD Sharing (as of September 2022): No"],"condition":["Advanced Malignancies","Endometrial cancer","Non-small cell lung cancer (NSCLC)","Melanoma","Mesothelioma","Neoplasms","Esophageal cancer","Ovarian cancer"],"disease":["Endometrial Cancer","Ovarian Cancer","Advanced Malignancies","Melanoma","Esophageal Cancer","Mesothelioma","Non-small Cell Lung Cancer (nsclc)","Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2251135"],"location":["United States"],"study_start_month":["10"],"keyword":["Advanced or metastatic cervical cancer","Merkel cell carcinoma","Ipilimumab","Hepatocellular carcinoma (HCC)","SCCHN","Triple-negative breast cancer","Squamous cell carcinoma of the head and neck","Small cell lung cancer (SLCL)","Nivolumab","Renal cell carcinoma (RCC)","MSI-H CRC","Urothelial carcinoma","TNBC","Microsatellite instability-high colorectal cancer","Gastric cancer (including stomach and gastroesophageal junction [GEJ])","OX40 ligand (OX40)"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies","description":"The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.","dates":{"creation":"2017-10-15"},"accession":"2251135","cross_references":{"ClinicalTrials___gov":["NCT03241173"]}}